Lungensonographie bei COVID‑19

Seibel, Armin; Heinz, Wolfgang; Greim, Clemens‐Alexander; Weber, Stefan

doi:10.1007/s00740-021-00403-2

Cited by 2 publications

(2 citation statements)

References 51 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers have spent time and effort finding a valuable and easy tool to evaluate these patients [ 4 ]. Due to the specific aspects of the infection, which mainly begins in the peripheral lung parenchyma, lung ultrasonography (LUS) is suitable as a diagnostic imaging method to identify suspected cases in the early disease phases [ 5 ]. LUS was identified for this purpose since the pandemic’s beginning.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: COVID-19 induces massive systemic inflammation. Researchers have spent much time and effort finding an excellent and rapid image tool to evaluate COVID-19 patients. Since the pandemic’s beginning, lung ultrasound (LUS) has been identified for this purpose. Monoclonal antibodies (mAb) were used to treat mild patients and prevent respiratory disease worsening. Materials and Methods: We evaluated 15 Caucasian patients with mild COVID-19 who did not require home oxygen, treated with Bamlanivimab and Etesevimab (Group 1). A molecular nose–throat swab test confirmed the diagnosis. All were office patients, and nobody was affected by respiratory failure. They were admitted to receive the single-day infusion of mAb treatment in agreement with the Italian Drug Agency (AIFA) rules for approval. LUS was performed before the drug administration (T0) and after three months (T1). We compared LUS at T1 in other outpatients who came for follow-up and were overlapping at the time of diagnosis for admittance criteria to receive mAb (Group 2). Results: Our COVID-19 outpatients reported no hospitalization in a follow-up visit after recovery. All patients became SARS-CoV-2 negative within one month since T0. LUS score at T0 was 8.23 ± 6.46. At T1 we found a significant decrease in Group 1 LUS score (5.18 ± 4.74; p < 0.05). We also found a significant decrease in the LUS score of Group 1 T1 compared to Group2 T1 (5.18 ± 4.74 vs 7.82 ± 5.21; p < 0.05). Conclusion: Early treatment of the SARS-CoV-2 virus effectively achieves a better recovery from disease and reduces lung involvement after three months as evaluated with LUS. Despite extrapolation to the general population may be done with caution, based on our data this ultrasound method is also effective for evaluating and following lung involvement in COVID-19 patients.

show abstract

Section: Introductionmentioning

confidence: 99%

“…LUS was identified for this purpose since the pandemic’s beginning. Serial ultrasound examinations on patients with confirmed COVID-19 can promptly detect changes in the affected lung tissue [ 5 , 6 ]. Moreover, many resources have been used to identify an adequate and effective treatment.…”

Section: Introductionmentioning

confidence: 99%